当前位置:
首页>产品中心>单抗/多抗>Ranibizumab ELISA Kit|Ranibizumab ELISA试剂盒(靶标:)
Ranibizumab ELISA Kit|Ranibizumab ELISA试剂盒(靶标:)
- 货号:RB9TDB941038
- 价格:面议
- 点击:215
产品介绍
产品参数
| 应用 | ELISA |
|---|
| 检测方法 | Colorimetric |
|---|
| 检测范围 | 234.4 ng/mL - 15, 000 ng/mL |
|---|
| 回收率 | 80-120% |
|---|
| 样本类型 | Plasma, Serum |
|---|
| 检测类型 | Quantitative |
|---|
| 稳定性和储存 | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃. |
|---|
| 运输条件 | 2-8 ℃ |
|---|
| 登录号 | P15692 |
|---|
| 背景信息 | Ranibizumab is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. Ranibizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Novartis, under the brand name Lucentis. Ranibizumab is used to treat wet age-related macular degeneration (AMD; an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities). It is also used to treat macular edema after retinal vein occlusion (an eye disease caused by blockage of blood flow from the eye that leads to blurry vision and vision loss), diabetic macular edema (an eye disease caused by diabetes that can lead to vision loss), and diabetic retinopathy (damage to the eyes caused by diabetes). It inhibits angiogenesis by inhibiting Vascular endothelial growth factor A (VEGF-A), and its effectiveness is similar to that of bevacizumab. Its rates of side effects also appear similar. However, ranibizumab typically costs $2, 000 a dose, while the equivalent dose of bevacizumab typically costs $50. |
|---|
| 别名 | Fab-12 variant Y0317, RhuFab, 347396-82-1 |
|---|
| 备注 | For Research Use Only. |
|---|
【仅供科学研究使用】
相关产品: